Testing everolimus and epoetin for liver transplant tolerance
Treatments studied
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 10 years after a liver transplant
- You take tacrolimus and do not take steroids as part of your anti-rejection medicines
- You do not have autoimmune liver disease or a history of recent rejection
- You have good kidney function (eGFR at least 40) and normal liver enzyme levels
- You are up to date on vaccinations and have no active infections (like TB, HIV, or hepatitis)
- You are not pregnant, do not use estrogen-based birth control, and have no history of blood clots or certain genetic disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
This study tests if some liver transplant patients can safely take lower doses of their immune-suppressing medicines, potentially reducing side effects. It uses a biomarker test to guide the treatment changes.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.